Top Markets
Coin of the day
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Rangering i aksjer #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Aksjekurs
$50.82
Sist synkronisert: 2026-08-11
Markedsverdi
$102.09M
Endring (1 dag)
1.90%
Endring (1 år)
-
Land
US
Handel Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Kategori

Aksjeprishistorikk for Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Høyeste sluttskurs: $50.63 den 2026-08-01

Laveste sluttskurs: $27.02 den 2026-05-01
Aksjeprishistorikk for Hemab Therapeutics Holdings, Inc. Common Stock fra 2026 til 2026
Årlig aksjeprisytelse
År Ytelse
Ikke nok data for de angitte datoene.
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH